Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Crispr Therapeutics Ag (CRSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,979,283
  • Shares Outstanding, K 52,279
  • Annual Sales, $ 3,120 K
  • Annual Income, $ -164,980 K
  • 60-Month Beta 3.13
  • Price/Sales 620.85
  • Price/Cash Flow N/A
  • Price/Book 4.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.88
  • Number of Estimates 3
  • High Estimate -0.82
  • Low Estimate -0.94
  • Prior Year -0.62
  • Growth Rate Est. (year over year) -41.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.00 +4.68%
on 02/25/19
42.03 -15.32%
on 03/04/19
+3.92 (+12.38%)
since 02/22/19
3-Month
22.36 +59.17%
on 12/24/18
42.03 -15.32%
on 03/04/19
+12.86 (+56.58%)
since 12/21/18
52-Week
22.22 +60.17%
on 12/21/18
73.90 -51.84%
on 05/24/18
-16.51 (-31.69%)
since 03/22/18

Most Recent Stories

More News
CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team...

CRSP : 35.59 (-6.00%)
S&P Reclaims 2800; NASDAQ’s Streak Hits 10 Weeks

S&P Reclaims 2800; NASDAQ’s Streak Hits 10 Weeks

SCVL : 30.74 (-3.27%)
CRSP : 35.59 (-6.00%)
TNDM : 68.76 (-6.53%)
UBNT : 144.27 (-2.08%)
TECD : 98.45 (-5.97%)
LASR : 22.39 (-3.12%)
FN : 51.37 (-5.62%)
ZS : 66.01 (-5.59%)
EDIT : 22.61 (-8.61%)
XPER : 23.09 (-5.02%)
INGN : 90.12 (-4.82%)
Biotech ETFs Jump on Roche-Spark Deal

The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

QURE : 63.43 (-7.28%)
SLDB : 10.24 (-2.94%)
PBE : 53.63 (-3.85%)
SBIO : 34.92 (-4.62%)
CRSP : 35.59 (-6.00%)
ARKG : 31.99 (-5.05%)
ONCE : 113.00 (-0.24%)
BLUE : 146.64 (-6.11%)
NVS : 93.42 (-0.26%)
BOLD : 36.90 (-6.68%)
RHHBY : 33.7600 (-1.06%)
XBI : 87.86 (-4.42%)
CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study

CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study....

CRSP : 35.59 (-6.00%)
VRTX : 181.53 (-0.56%)
EDIT : 22.61 (-8.61%)
NTLA : 16.16 (-8.29%)
Biotech ETFs Jump on Roche-Spark Deal

The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

QURE : 63.43 (-7.28%)
SLDB : 10.24 (-2.94%)
PBE : 53.63 (-3.85%)
SBIO : 34.92 (-4.62%)
CRSP : 35.59 (-6.00%)
ARKG : 31.99 (-5.05%)
ONCE : 113.00 (-0.24%)
BLUE : 146.64 (-6.11%)
NVS : 93.42 (-0.26%)
BOLD : 36.90 (-6.68%)
RHHBY : 33.7600 (-1.06%)
XBI : 87.86 (-4.42%)
Deal on the Way Now that Deadline is Delayed?

Deal on the Way Now that Deadline is Delayed?

CARB : 24.40 (-1.49%)
QURE : 63.43 (-7.28%)
JBLU : 15.93 (-2.27%)
CRSP : 35.59 (-6.00%)
SPR : 89.40 (-3.36%)
ATH : 41.13 (-5.23%)
LYV : 62.95 (-2.07%)
ANF : 24.66 (-2.91%)
NMRK : 8.35 (-5.76%)
CBRE : 48.25 (-2.96%)
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

-First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia-

CRSP : 35.59 (-6.00%)
CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001

-First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia-

CRSP : 35.59 (-6.00%)
VRTX : 181.53 (-0.56%)
Strong Friday Close Secures a 9th Week in the Green

Strong Friday Close Secures a 9th Week in the Green

LULU : 143.21 (-3.83%)
CRSP : 35.59 (-6.00%)
ETSY : 66.02 (-4.93%)
ILMN : 308.79 (-3.26%)
OSPN : 18.79 (-6.28%)
EQT : 19.51 (-3.70%)
BKD : 6.78 (-3.00%)
RDWR : 25.69 (-1.87%)
XNCR : 29.94 (-6.73%)
KTOS : 15.63 (-3.16%)
CRISPR Therapeutics Proposes New Members to the Board of Directors

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect John T. Greene and Katherine...

CRSP : 35.59 (-6.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade CRSP with:

Business Summary

CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

See More

Key Turning Points

2nd Resistance Point 39.08
1st Resistance Point 37.33
Last Price 35.59
1st Support Level 34.51
2nd Support Level 33.44

See More

52-Week High 73.90
Fibonacci 61.8% 54.16
Fibonacci 50% 48.06
Fibonacci 38.2% 41.96
Last Price 35.59
52-Week Low 22.22

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar